REGN — Regeneron Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $66.35bn
- $60.31bn
- $14.34bn
Brief: Otarmeni Receives EMA Filing Acceptance For Genetic Hearing Loss
Biopharmaceutical firm Parabilis Medicines files for US IPO (updated)
U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology
U.S. STOCKS ON THE MOVE-Eli Lilly, BlackRock TCP Capital, Boston Scientific
U.S. STOCKS ON THE MOVE-Cognizant, Coursera, ServiceNow
U.S. STOCKS ON THE MOVE-Ford Motor, Intel, Hims & Hers Health
Street View: Regeneron's melanoma trial setback raises bigger-picture questions
Regeneron drops after skin cancer treatment misses late-stage trial goal (updated)
U.S. STOCKS ON THE MOVE-Macy's, Dominion Energy, Bio-Rad Laboratories
Brief: Regeneron Announces Strategic Collaboration With Parabilis Medicines To Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas
Regeneron drops after skin cancer treatment misses late-stage trial goal
Regeneron slides after skin cancer drug combo misses trial goal
U.S. RESEARCH ROUNDUP- Exxon Mobil, Northrop Grumman, Regeneron Pharmaceuticals
Brief: Regeneron Provides Update On Phase 3 Trial Of Fianlimab (Lag-3 Inhibitor) Combination In First-Line Unresectable Or Metastatic Melanoma
Brief: Next Generation Of Scientific Leaders Awarded More Than $7 Million At The 2026 Regeneron International Science And Engineering Fair
EyePoint's late-stage eye drug trials to continue after safety panel review (updated)
EyePoint's late-stage eye drug trials to continue after safety panel review
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
U.S. RESEARCH ROUNDUP-Alphabet, Amazon, Meta